Fezakinumab

Fezakinumab

Monoclonal antibody
Type	Whole antibody
Target	IL-22
Clinical data
ATC code	none
Identifiers
CAS Number	1007106-86-6^N
ChemSpider	none
UNII	0S77U25XZ3
KEGG	D09615
Chemical and physical data
Formula	C6408H9873N1706O2016S44
Molar mass	144479.04 g·mol^−1
^NY (what is this?)  (verify)

Fezakinumab is a human monoclonal antibody against interleukin-22,^[1] designed for the treatment of psoriasis and rheumatoid arthritis.^[2]

Research and development

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,^[3] but data were not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.^[4]

References

1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
2. "Pfizer Pipeline" (PDF). 28 February 2011. Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.
3. "Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Living Medical eTextbook - Rheumatology - Projects In Knowledge. p. 4. Archived from the original on 24 January 2018. Retrieved 2017-06-07.
4. Richardson B. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Archived from the original on 25 January 2018. Retrieved 24 January 2018.